drugset / Trial / NCT05470725
Study to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal Function
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1, open-label, parallel-group study in subjects with varying degrees of renal function to assess the safety, tolerability, and Pharmacokinetics of a single 10 mg oral dose of CIN-107.
Timeline
- Start
- 2021-01-12
- Primary completion
- 2021-04-30
- Completion
- 2021-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Baxdrostat | Small molecule | 10 mg | Oral |